Literature DB >> 22752198

Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening.

Ah-Fong Hoo1, Lena P Thia, The Thanh Diem Nguyen, Andrew Bush, Jane Chudleigh, Sooky Lum, Deeba Ahmed, Ian Balfour Lynn, Siobhan B Carr, Richard J Chavasse, Kate L Costeloe, John Price, Anu Shankar, Colin Wallis, Hilary A Wyatt, Angela Wade, Janet Stocks.   

Abstract

BACKGROUND: Long-term benefits of newborn screening (NBS) for cystic fibrosis (CF) have been established with respect to nutritional status, but effects on pulmonary health remain unclear. HYPOTHESIS: With early diagnosis and commencement of standardised treatment, lung function at ∼3 months of age is normal in NBS infants with CF.
METHODS: Lung clearance index (LCI) and functional residual capacity (FRC) using multiple breath washout (MBW), plethysmographic (pleth) FRC and forced expirations from raised lung volumes were measured in 71 infants with CF (participants in the London CF Collaboration) and 54 contemporaneous healthy controls age ∼3 months.
RESULTS: Compared with controls, and after adjustment for body size and age, LCI, FRC(MBW) and FRC(pleth) were significantly higher in infants with CF (mean difference (95% CI): 0.5 (0.1 to 0.9), p=0.02; 0.4 (0.1 to 0.7), p=0.02 and 0.9 (0.4 to 1.3), p<0.001, z-scores, respectively), while forced expiratory volume (FEV(0.5)) and flows (FEF(25-75)) were significantly lower (-0.9 (-1.3 to -0.6), p<0.001 and -0.7 (-1.1 to -0.2), p=0.004, z-scores, respectively). 21% (15/70) of infants with CF had an elevated LCI (>1.96 z-scores) and 25% (17/68) an abnormally low FEV(0.5) (below -1.96 z-scores). While only eight infants with CF had abnormalities of LCI and FEV(0.5), using both techniques identified abnormalities in 35% (24/68). Hyperinflation (FRC(pleth) >1.96 z-scores) was identified in 18% (10/56) of infants with CF and was significantly correlated with diminished FEF(25-75) (r=-0.43, p<0.001) but not with LCI or FEV(0.5).
CONCLUSION: Despite early diagnosis of CF by NBS and protocol-driven treatment in specialist centres, abnormal lung function, with increased ventilation inhomogeneity and hyperinflation and diminished airway function, is evident in many infants with CF diagnosed through NBS by 3 months of age.

Entities:  

Mesh:

Year:  2012        PMID: 22752198     DOI: 10.1136/thoraxjnl-2012-201747

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

1.  European Respiratory Society International Congress best abstract preview from the allied respiratory professionals from assembly 9.

Authors:  Jason Blonshine; Joana Cruz; Andreja Sajnic; Jana De Brandt
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Sonographic evidence of abnormal tracheal cartilage ring structure in cystic fibrosis.

Authors:  Amit Diwakar; Ryan J Adam; Andrew S Michalski; Monelle M Tamegnon; Anthony J Fischer; Jan L Launspach; Rebecca A Horan; Simon C Kao; Kathryn Chaloner; David K Meyerholz; David A Stoltz
Journal:  Laryngoscope       Date:  2015-03-30       Impact factor: 3.325

3.  Early pulmonary disease manifestations in cystic fibrosis mice.

Authors:  Rebecca J Darrah; Anna L Mitchell; Cara K Campanaro; Eric S Barbato; Paul Litman; Abdus Sattar; Craig A Hodges; Mitchell L Drumm; Frank J Jacono
Journal:  J Cyst Fibros       Date:  2016-05-24       Impact factor: 5.482

4.  Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.

Authors:  Padmaja Subbarao; Carlos Milla; Paul Aurora; Jane C Davies; Stephanie D Davis; Graham L Hall; Sonya Heltshe; Philipp Latzin; Anders Lindblad; Jessica E Pittman; Paul D Robinson; Margaret Rosenfeld; Florian Singer; Tim D Starner; Felix Ratjen; Wayne Morgan
Journal:  Ann Am Thorac Soc       Date:  2015-06

5.  Early airway structural changes in cystic fibrosis pigs as a determinant of particle distribution and deposition.

Authors:  Maged Awadalla; Shinjiro Miyawaki; Mahmoud H Abou Alaiwa; Ryan J Adam; Drake C Bouzek; Andrew S Michalski; Matthew K Fuld; Karen J Reynolds; Eric A Hoffman; Ching-Long Lin; David A Stoltz
Journal:  Ann Biomed Eng       Date:  2013-12-06       Impact factor: 3.934

6.  Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline.

Authors:  Padmaja Subbarao; Sanja Stanojevic; Meghan Brown; Renee Jensen; Margaret Rosenfeld; Stephanie Davis; Lyndia Brumback; Per Gustafsson; Felix Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2013-08-15       Impact factor: 21.405

7.  Chloral hydrate sedation for infant pulmonary function testing.

Authors:  Clement L Ren; Paul Robinson; Sarath Ranganathan
Journal:  Pediatr Pulmonol       Date:  2014-02-24

Review 8.  Background and Epidemiology.

Authors:  Don B Sanders; Aliza K Fink
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

9.  Hypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung disease.

Authors:  Simon Y Graeber; Zhe Zhou-Suckow; Jolanthe Schatterny; Stephanie Hirtz; Richard C Boucher; Marcus A Mall
Journal:  Am J Respir Cell Mol Biol       Date:  2013-09       Impact factor: 6.914

Review 10.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.